Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats
about
Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic diseaseExtending the translational potential of targeting NO/cGMP-regulated pathways in the CVSRiociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI/PET imagingEffects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockadeChronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in ratsDevelopment of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Cyclic nucleotide signalling in kidney fibrosis.Cardiac NO signalling in the metabolic syndrome.Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy.Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment.Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock.Stimulators of soluble guanylyl cyclase: future clinical indicationsRiociguat: first global approval.Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic diseaseRiociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?Effect of QiShenYiQi Pill on Myocardial Collagen Metabolism in Rats with Partial Abdominal Aortic Coarctation.Cytochrome b5 Reductase 3 Modulates Soluble Guanylate Cyclase Redox State and cGMP Signaling.Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension.Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension.Antenatal excessive sodium intake induces adverse vascular remodelling in offspring
P2860
Q26827629-D798DBC9-F5F2-4F99-895C-353244B8686FQ27021649-56AAEFA2-1610-44C4-A535-D5B9AC97A00EQ27336286-58EDD835-B81A-4FF6-80FC-765A1597EEB6Q28482185-1936FBB8-2FD2-46C5-A34A-EAD052CCA725Q30315850-2DE2ED70-8346-495E-9253-719FB631ADDBQ33596457-D3C907CA-92FC-4E1E-9D88-F4E75D787366Q34389618-9D68038E-3DC1-4A3D-8060-30515A3E834CQ34538482-70F77259-AD2F-493A-9858-1523DE1DB2FDQ35075847-9D993C06-1BE2-415F-BA80-FEC22F41B9F5Q35138860-A7952EC0-08C8-456B-B539-C96DAEAD3335Q35204828-CFECC226-361B-4560-B92A-DFB9B6FFE40DQ36363156-3839FEA2-2310-443C-A9A5-E26445A2D415Q36380981-DE21F028-7E2D-499E-AFED-C9FD39D77C9BQ36881711-A0F42D48-E52B-4970-8EF5-3A78146984C7Q37616946-715A9EBF-FD06-484C-B0A6-DF2519AB211AQ37734554-B0BF4123-C252-46A9-A1C1-80BB2DAD3CCBQ38093420-07BB038E-52E8-4B3B-AD0A-E0C972BE4C5AQ38161841-14939425-72F1-44B0-983D-C7B4C343B104Q38202115-2F8D4574-F5C5-40A3-A538-1B0E9CF5A11CQ38263468-10B45975-2C78-432B-828A-FA7AE81F392AQ38818606-321EA03A-79FE-4010-AA68-717B65E7EE58Q38818645-229B15D9-F625-4F73-BD17-BB975A67F0C1Q42678247-96D0E611-DD68-4177-B815-3F3C01FB118AQ45060738-EAE2652C-2AD1-4899-A628-A2A0AC720B95Q49419669-9EE667FE-748A-42CE-9FE7-BA226CB9CA48Q52670776-FDC3773C-3655-4E25-9F8E-4A0771D38D19Q54375096-B2B49828-148B-46F3-B392-A79F00DA89E3Q54935988-7C86BD90-9DB3-4661-A4CE-EC7E8587627DQ57789849-5E24D1F9-C319-401D-83C1-5C7D1D807AF6
P2860
Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Soluble guanylate cyclase stim ...... al in salt-sensitive Dahl rats
@ast
Soluble guanylate cyclase stim ...... al in salt-sensitive Dahl rats
@en
Soluble guanylate cyclase stim ...... al in salt-sensitive Dahl rats
@nl
type
label
Soluble guanylate cyclase stim ...... al in salt-sensitive Dahl rats
@ast
Soluble guanylate cyclase stim ...... al in salt-sensitive Dahl rats
@en
Soluble guanylate cyclase stim ...... al in salt-sensitive Dahl rats
@nl
prefLabel
Soluble guanylate cyclase stim ...... al in salt-sensitive Dahl rats
@ast
Soluble guanylate cyclase stim ...... al in salt-sensitive Dahl rats
@en
Soluble guanylate cyclase stim ...... al in salt-sensitive Dahl rats
@nl
P2093
P2860
P3181
P1433
P1476
Soluble guanylate cyclase stim ...... al in salt-sensitive Dahl rats
@en
P2093
Andreas Hucke
Axel Kretschmer
Bettina Lawrenz
Oleg V Evgenov
Sandra Geschka
Yuliya Sharkovska
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0021853
P407
P577
2011-01-01T00:00:00Z